National Bankshares Has Lowered Expectations for DRI Healthcare Trust (TSE:DHT.UN) Stock Price

DRI Healthcare Trust (TSE:DHT.UN) had its price objective dropped by stock analysts at National Bankshares from C$19.50 to C$17.50 in a report issued on Thursday,BayStreet.CA reports. The brokerage currently has an “outperform” rating on the stock. National Bankshares’ target price points to a potential upside of 45.35% from the company’s current price.

A number of other research analysts have also weighed in on DHT.UN. Raymond James decreased their target price on DRI Healthcare Trust from C$23.00 to C$22.00 in a report on Wednesday, November 13th. CIBC cut their target price on shares of DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating for the company in a research note on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, DRI Healthcare Trust presently has an average rating of “Moderate Buy” and a consensus price target of C$17.94.

DRI Healthcare Trust Price Performance

TSE:DHT.UN opened at C$12.04 on Thursday. The firm has a fifty day simple moving average of C$11.97 and a 200 day simple moving average of C$12.57. DRI Healthcare Trust has a 1-year low of C$10.39 and a 1-year high of C$17.43.

DRI Healthcare Trust Company Profile

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.